Can NGS-based clinical metagenomics outperform standard urine culture
for comprehensive uropathogen detection and antibiotic resistance
prediction? Urinary tract infections (UTIs) are common, leading to 10
million office visits per year. Quick and accurate identification of
uropathogens and antimicrobial susceptibility is critical to the
management of UTIs as well as prevention of increased antimicrobial
resistance. Today’s standard urine culture is limited in scope where
up to 20% of women will have a negative urine culture despite showing
symptoms. Standard urine culture and susceptibility can take up to 1
week, delaying appropriate UTI management.
Clinical
metagenomics enables culture-free, hypothesis-free detection and
identification of uropathogens and genetic markers of antibiotic
resistance. By coupling the power of Illumina’s next-generation
sequencing and IDbyDNA’s robust Explify analytics solutions, a
streamlined specimen-to-report workflow can be performed in 24 hours
resulting in comprehensive uropathogen detection.
Robert Schlaberg, MD, PhD, MPH
Co-Founder, Chief Medical Officer
IDbyDNA
Mehdi Keddache, PhD
Executive Sales Specialist, Microbiology
Illumina
Your email address is never shared with third parties.